A Phase I/II Randomized Study of Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer.

Trial Profile

A Phase I/II Randomized Study of Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2014

At a glance

  • Drugs TgDCC E1A gene therapy (Primary) ; Paclitaxel
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Aug 2012 Actual end date (1 Jul 2012) added as reported by ClinicalTrials.gov.
    • 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Mar 2012 Planned End Date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top